Radboud university medical center study sets new milestone with 90% diagnostic accuracy of lung nodules suspected of cancer using Philips technology for bronchoscopic procedures
06 Oktober 2021 - 02:00PM
Radboud university medical center study sets new milestone with 90%
diagnostic accuracy of lung nodules suspected of cancer using
Philips technology for bronchoscopic procedures
October 4, 2021
Radboud university medical center study sets new
milestone with 90% diagnostic accuracy of lung nodules suspected of
cancer using Philips technology for bronchoscopic
procedures
Hospital achieves world-first level of improvement in the
diagnostic accuracy of navigation bronchoscopy using Philips Lung
Suite combined with the company’s Image Guided Therapy System –
Azurion
Amsterdam, the Netherlands – Royal Philips
(NYSE: PHG, AEX: PHIA), a global leader in health technology, and
Radboud university medical center (Radboudumc), a leading Dutch
academic research and teaching hospital (Nijmegen, the
Netherlands), have announced the positive results of a clinical
study conducted by Radboudumc aimed at setting a new standard of
safety and accuracy in the diagnosis of small peripheral lung
lesions. The study outcomes represent a promising milestone in the
global innovation effort to set a new clinical standard for
detecting lung cancer at an early stage, potentially leading to
improved prognoses for patients.
Radboudumc’s observational study reported the diagnostic
accuracy and procedural radiation dose for patients undergoing an
endobronchial lung biopsy supported by Philips Lung Suite - a
solution that uses 3D imaging with augmented fluoroscopy to support
high precision diagnosis and minimally-invasive therapy in one
room. Diagnostic accuracy of 90% was reported while reducing
the average total effective radiation dose per procedure by more
than half from 47.5 Gy·cm2 (effective dose: 14.3 mSv) to 25.4
Gy·cm2 (effective dose: 5.8 mSv). The median long-axis diameter of
the 248 lesions navigated to during the study was 13 mm (range
5-65mm). The results of the study were published in the October
2021 issue of the Journal of Bronchology & Interventional
Pulmonology: Volume 28 - Issue 4 [1].
“The airways and lungs are very challenging places to biopsy, so
we need good navigation to make sure we reach the target location,”
said Dr. Erik van der Heijden, Pulmonologist and Associate
Professor of Interventional Pulmonary Diseases at Radboudumc, who
led the study. “Philips’ 3D imaging solution allows us to create
real-time 3D visualizations enabling us to follow the correct path
from different angles to where we need to be, which is particularly
useful for very small abnormalities. Our study confirmed that it
increases the accuracy and safety of the biopsy procedure,
improving results for patients. Philips’ technology also offers the
promising outlook that we could not only diagnose but also
immediately treat these early-stage patients using novel procedures
such as tumor ablation.”
Lung cancer – the leading cause of cancer
deathLung cancer kills around 1.7 million people a year
worldwide. That makes it the leading cause of cancer death globally
[2], accounting for greater loss of life than breast, colon, and
prostate cancer combined. While early diagnosis and treatment are
critical to better outcomes and quality of life, the majority of
lung cancers are currently diagnosed at a late stage, with minimal
chance of a surgical cure.
Early detection and diagnosis key to
survivabilityThe research being carried out at Radboudumc
focuses on the diagnosis of early-stage lung cancer lesions,
typically detected during routine screening of high-risk patient
groups or discovered and reported as so-called ‘incidental
findings’ when a patient has a chest scan for some other reason. A
tissue sample typically then needs to be obtained that a
pathologist can use to make a definitive diagnosis.
Challenging for clinicians to accurately
navigateA new method is image-guided endobronchial lung
biopsy, during which a clinician uses live image guidance to
maneuver through the airways in the lungs to advance a catheter
towards the lesion. However, the airways in the lungs are a complex
network that requires accurate navigation to remove the required
tissue sample. Until now, image-guided endobronchial lung biopsy
has only really been effective when an abnormality or tumor is
located in or near one of the larger airways in the lungs, and even
then it is challenging for clinicians to accurately navigate when
looking at a 2D greyscale fluoroscopy image while the lungs are
moving as the patient breathes.
Philips Lung Suite enables all-in-one lung cancer diagnosis and
treatment. It provides advanced real-time 3D imaging with augmented
fluoroscopy on the company’s Image Guided Therapy System – Azurion,
combined with dedicated software. With Philips’ Cone Beam CT
imaging, the X-ray detector rotates around the patient to generate
a CT-like image in around five seconds, providing clinicians
with a high-resolution 3D view of the target lesion and other
anatomical structures. This allows the clinician performing the
biopsy procedure to be continually guided by high-quality real-time
imaging to advance a catheter towards the lesion through a
bronchoscope. Once done, its position can be confirmed in real-time
using the same imaging modality and a biopsy sample removed.
Philips has a comprehensive portfolio of lung cancer diagnosis
and treatment solutions. In addition to Philips Lung Suite, the
company’s Lung Cancer Orchestrator provides an integrated lung
cancer patient management system for both CT lung screening
programs and incidental pulmonary findings programs that manages
and monitors patients every step of the way in their lung cancer
screening and treatment decision journey.
Read this interview with Dr. Erik van der Heijden on his
personal experiences using Philips 3D imaging and navigation
platform during image-guided endobronchial lung biopsy.
[1] Journal of Bronchology & Interventional Pulmonology:
October 2021 - Volume 28 - Issue 4 - p 262-271 doi:
10.1097/LBR.0000000000000783[2] CA CANCER J CLIN 2021;71:7–33,
Cancer Statistics 2021:
https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.3322/caac.21654
For further information, please contact:
Joost MalthaPhilips Global Press OfficeTel: +31 610 558
116Email: joost.maltha@philips.com
Fabienne van der FeerPhilips Image Guided TherapyTel: +31 622
698 001Email: fabienne.van.der.feer@philips.com
About Royal Philips Royal Philips (NYSE: PHG,
AEX: PHIA) is a leading health technology company focused on
improving people's health and well-being, and enabling better
outcomes across the health continuum – from healthy living and
prevention, to diagnosis, treatment and home care. Philips
leverages advanced technology and deep clinical and consumer
insights to deliver integrated solutions. Headquartered in the
Netherlands, the company is a leader in diagnostic imaging,
image-guided therapy, patient monitoring and health informatics, as
well as in consumer health and home care. Philips generated 2020
sales of EUR 17.3 billion and employs approximately 77,000
employees with sales and services in more than 100 countries. News
about Philips can be found
at http://www.philips.com/newscenter
- Dr. Erik van der Heijden Radboudumc Nijmegen
- Lung biopsy using Philips 3D navigation - 1
- Lung biopsy using Philips 3D navigation - 2
Koninklijke Philips NV (BIT:1PHIA)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Koninklijke Philips NV (BIT:1PHIA)
Historical Stock Chart
Von Mär 2023 bis Mär 2024